Observational studyBMJ open2026
Multicentre, prospective, observational study on the effectiveness and safety of upadacitinib for active perianal fistulising Crohn's disease in patients with prior anti-tumour necrosis factor failure: a study protocol.
Observational study in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPerianal fistulising Crohn's disease (pfCD) is a debilitating phenotype and remains a therapeutic challenge. Current guidelines recommend anti-tumour necrosis factor agents as first-line therapy for pfCD; however, there is still no consensus on the optimal pharmacological strategy once anti-TNF therapy fails. Upadacitinib, an oral selective Janus kinase 1 inhibitor, has demonstrated efficacy in moderate-to-severe Crohn's disease. Nevertheless, real-world data specifically addressing its effectiveness and safety in the refractory pfCD population remain scarce. This study aims to evaluate the real-world effectiveness and safety of upadacitinib in patients with active pfCD who have failed anti-TNF therapy. METHODS AND ANALYSIS: This is a multicentre, prospective, observational cohort study. A total of 90 adult patients with Crohn's disease-associated perianal fistulas with active drainage and refractory to prior therapy with infliximab or adalimumab will be enrolled. Patients with severe luminal disease, undrained abscesses >2 cm, anal stenosis or diverting stomas will be excluded. Participants will receive upadacitinib 45 mg/day during the induction phase, followed by 15 or 30 mg/day during maintenance. All treatment decisions are made according to routine clinical practice and local product labels, not mandated by the study protocol, including upadacitinib dosing, dose adjustments and concomitant therapies. The primary outcome is a composite of clinical and radiological fistula response at week 12. Secondary outcomes, assessed at weeks 12 and 52, include perianal fistula-related, CD-related and safety outcomes. ETHICS AND DISSEMINATION: Shanghai Jiao Tong University School of Medicine, Renji Hospital Ethics Committee has reviewed and approved this study (Approval No: LY2025-024-A). Findings will be disseminated through publication in peer-reviewed journals, presentations at scientific conferences and summaries provided to the participating institutions and relevant patient communities. TRIAL REGISTRATION NUMBER: ChiCTR2600117355.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.